Clinical trials: Metastatic Malignant Neoplasm in the Bone
Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family.
- Conditions
- Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- TAGNOT (NCT07292168)
- Testing
- humanized monoclonal anti-FGFR1 antibody OM-RCA-01
- Where
- 5 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Kidney Cancer Research Bureau
Bone Metastases
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)
Highly selective irradiation requires accurate target definition by high-resolution three-dimensional imaging. Co-registration of FDG-PET and high-resolution CT might be the imaging modality of choice.
- Trial name
- NCT00503178
- Testing
- Biological imaging guided antalgic radiotherapy
- Where
- Belgium
- Volunteers
- 54 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer, Castration-resistant Prostate Cancer
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard testing in an attempt to gain…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone
- Trial name
- NCT02346526
- Testing
- Blood Tests, CT scan, FACBC PET/MRI in a subset of participants
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer With Bone Metastasis
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.
- Trial name
- NCT00241111
- Testing
- zoledronic acid
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Bone Lesion
Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow
The purpose of this research study is to evaluate the safety and effectiveness of an experimental procedure called Focused Radiation that may result in a faster way to plan and deliver radiation for the treatment of pain caused…
- Trial name
- NCT02145286
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Paul W. Read, MD
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen
Prostatic Neoplasm
Treatment Patterns in Metastatic Prostate Cancer
This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives).
- Trial name
- NCT02729103
- Testing
- Xofigo (Radium 223 dichloride,BAY88-8223)
- Where
- United States
- Volunteers
- 565 people
- Sponsor
- Bayer
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Hypercalcemia of Malignancy
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
RATIONALE: Ibandronate and zoledronate may help relieve some of the symptoms caused by bone metastases. It is not yet know whether ibandronate is more effective than zoledronate in treating bone metastases from breast cancer.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer
- Trial name
- NCT00326820
- Testing
- ibandronate sodium, zoledronic acid, Zolendronic Acid
- Where
- 79 sites in United Kingdom
- Volunteers
- 1,404 people
- Sponsor
- Wales Cancer Trials Unit
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Prostate Carcinoma
Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs.
- Trial name
- α-RT (NCT02484339)
- Testing
- Radium-223 dichloride, Conventional or high dose radiotherapy
- Where
- 6 sites in Germany
- Volunteers
- 274 people
- Sponsor
- University Hospital Freiburg
Sarcoma, Soft Tissue Sarcoma
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor
- Trial name
- NCT04634227
- Testing
- Ascorbate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Iowa
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Non-small Cell Lung Cancer, Bone Metastases
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone…
- Trial name
- BLEST (NCT00765687)
- Testing
- bisphosphates
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth.
- Conditions
- Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
- Trial name
- NCT03707184
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
This phase Ib/II trial studies the safety, side effects, best dose, and effectiveness of ribociclib when given with enzalutamide in treating patients with castrate-resistant prostate cancer that has spread from the primary site…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02555189
- Testing
- Enzalutamide, Ribociclib, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Bone Metastases
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
To compare increasing doses and different treatment schedules of stereotactic body radiation therapy (SBRT) against standard treatment scheduling.
- Trial name
- NCT06065449
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Bone Metastasis, Gastrointestinal Cancer
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
Bone metastasis causes bone destruction and skeletal related events (SRE) including compression fracture, hypercalcemia, and spinal cord compression.
- Trial name
- NCT02784652
- Testing
- Zoledronic acid, Radiotherapy
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Severance Hospital
Bone Metastases, Radiotherapy
Single frActIoN eighT Gray Palliative Radiotherapy With Modulated Intensity for Pain Reduction
Non-randomized, monocentric, observational study to evaluate the response in terms of reduction of painful symptoms from bone metastases to radiotherapy with high personalization of treatment: performed with modern technology…
- Conditions
- Bone Metastases, Radiotherapy, Technology
- Trial name
- SAINT (NCT03554135)
- Testing
- Personalization of palliative radiotherapy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS